论文部分内容阅读
目的:研究氢化可的松琥珀酸钠联合还原型谷胱甘肽治疗支气管哮喘疗效。方法:将144例支气管哮喘患者随机分入治疗组73例和对照组71例。所有支气管哮喘患者均接受抗炎、解痉平喘及对症支持治疗。治疗组另给予氢化可的松琥珀酸钠和还原型谷胱甘肽。治疗前后分别观察症状、体征改变及住院时间,同时分别进行哮喘控制测试(ACT),检测FEV1和呼出气一氧化氮水平(FeNO)。结果:治疗前两组以上观察指标比较均无统计学差异。治疗组总有效率91.8%高于对照组78.9%(P<0.05)。治疗组咳嗽、气喘、和哮鸣音消失时间均较对照组短(P<0.05),治疗组住院天数5.92±1.08天,对照组为8.91±1.56天,组间比较差异有统计学意义(P<0.05)。治疗后比较,治疗组ACT评分较对照组高(P<0.05),治疗组FEV1水平为2.92±0.90L,高于对照组为2.08±0.93L(P<0.05),治疗后FENO水平比较,治疗组低于对照组(P<0.01)。结论:氢化可的松琥珀酸钠联合还原型谷胱甘肽治疗支气管哮喘可提高治疗有效率,有效控制哮喘的症状体征,缩短住院时间。同时提高ACT评分、FEV1水平,降低FeNO。
Objective: To study the efficacy of hydrocortisone sodium succinate combined with reduced glutathione in the treatment of bronchial asthma. Methods: 144 patients with bronchial asthma were randomly divided into treatment group (73 cases) and control group (71 cases). All patients with bronchial asthma received anti-inflammatory, antispasmodic and anti-asthmatic symptomatic and supportive care. The treatment group was additionally given hydrocortisone sodium succinate and reduced glutathione. The symptoms, signs and hospital stay were observed before and after treatment. The asthma control test (ACT), FEV1 and exhaled nitric oxide (FeNO) were also performed. Results: There was no significant difference in the above two groups before treatment. The total effective rate in the treatment group was 91.8% higher than that in the control group (78.9%, P <0.05). The duration of cough, asthma and wheeze disappearance in the treatment group was shorter than that in the control group (P <0.05). The days of hospitalization in the treatment group were 5.92 ± 1.08 days and 8.91 ± 1.56 days in the control group, and the difference was statistically significant (P <0.05). After treatment, the ACT score in the treatment group was higher than that in the control group (P <0.05). The FEV1 level in the treatment group was 2.92 ± 0.90L, which was higher than that in the control group (2.08 ± 0.93L, P <0.05) Group was lower than the control group (P <0.01). Conclusion: Hydrocortisone sodium succinate combined with reduced glutathione in the treatment of bronchial asthma can improve the treatment efficiency, effectively control the symptoms and signs of asthma and shorten the hospital stay. At the same time improve ACT score, FEV1 level, reduce FeNO.